Medical devices

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

Retrieved on: 
Thursday, July 29, 2021
Oncology, Health, FDA, Medical devices, General Health, Radiology, Pharmaceutical, Branches of biology, Anatomy, Cancer, Histopathology, Prostate cancer, Glutamate carboxypeptidase II, Prostate, Gallium scan, Prostate cancer screening, Prostate Cancer, PYLARIFY® (piflufolastat F 18) Injection, Lantheus Holdings, Inc., PROSTATE CANCER, PYLARIFY® (PIFLUFOLASTAT F 18) INJECTION, LANTHEUS HOLDINGS, INC.

A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Key Points: 
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues.
  • aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
  • PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.

COPD Foundation Condemns Big Tobacco Acquisition of Pharmaceutical Company

Retrieved on: 
Thursday, July 29, 2021
Other Health, General Health, Pharmaceutical, Philanthropy, Oncology, Medical devices, Infectious diseases, Retail, Foundation, Science, Other Science, Health, Health effects of tobacco, Chronic lower respiratory diseases, Chronic obstructive pulmonary disease

The COPD Foundation condemns this acquisition.

Key Points: 
  • The COPD Foundation condemns this acquisition.
  • A company that profits from the sale of products that cause COPD should not benefit from the sale of products that treat COPD.
  • Patients, Providers, Payers, and Pharmacies will likely face the ethical dilemma as to whether it is appropriate to use treatments that profit Big Tobacco, stated Dr. Byron Thomashow, COPD Foundations Chief Medical Officer.
  • The position of Phillip Morris that those who oppose the alliance of Big Tobacco and Pharma are promoting the continuing sale of tobacco products is preposterous.

Strategic Partnership Between Genedata and SCIEX Deepens and Accelerates Characterization of Next Generation Biotherapeutics

Retrieved on: 
Thursday, July 29, 2021
Data management, Biotechnology, Technology, Health, Pharmaceutical, Medical devices, Research, Software, Genetics, Science, Hardware, Genedata, Information technology management, Workflow, Business process management, Articles, Information technology, Business, SCIEX, Genedata, SCIEX, GENEDATA

The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata Expressionist enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .

Key Points: 
  • The goal of this partnership is to jointly innovate new workflows that leverage the proven Genedata Expressionist enterprise software platform and the analytical power of new SCIEX hardware such as the ZenoTOF 7600 system .
  • This will ultimately accelerate discovery, development, and commercialization of novel biopharmaceuticals, while reducing costs by streamlining and automating complex analytical processes.
  • However, they also tell us the complexity of these molecules presents a significant characterization challenge in both analytics and data processing.
  • This strategic partnership with Genedata will enable the development of customized data processing workflows to address key customer challenges, so that therapies can progress through the development pipeline faster.

QIAGEN Reports Full Results for Q2 and H1 2021

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Genetics, Research, Science, Biotechnology, Medical software, Qiagen, United States dollar, Economies, Currency

Net sales rose 28% (+24% at constant exchange rates, CER) to $567.3 million in Q2 2021 and above the outlook for about 20% CER growth.

Key Points: 
  • Net sales rose 28% (+24% at constant exchange rates, CER) to $567.3 million in Q2 2021 and above the outlook for about 20% CER growth.
  • Currency movements against the U.S. dollar had a positive impact of about four percentage points on sales at actual rates in Q2 2021 over the year-ago period.
  • For the first half of 2021, net sales rose 39% (+35% CER) to $1.135 billion.
  • As of June 30, 2021, QIAGEN employed more than 5,900 people in over 35 locations worldwide.

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Oncology, Medical devices, Angiography, Projectional radiography, Genuity

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m.

Key Points: 
  • AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m.
  • A live webcast of the presentation will be accessible through the Investors section of the Companys website at www.angiodynamics.com and will be available for replay following the event.
  • AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology.
  • AngioDynamics diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products.

Baxter to Present at UBS Genomics 2.0 and MedTech Innovations Summit

Retrieved on: 
Thursday, July 29, 2021
Surgery, Medical devices, Medical Supplies, Hospitals, Genetics, Fitness & Nutrition, Biotechnology, Health, Pharmaceutical, Companies, Finance, Banks, Baxters, Zimmer Biomet Robotics, Bax, UBS, Caregiver

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif. Jay Saccaro, Baxters chief financial officer, is scheduled to present at 10:00 a.m. Pacific Time.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif. Jay Saccaro, Baxters chief financial officer, is scheduled to present at 10:00 a.m. Pacific Time.
  • The live webcast of Baxters presentation can be accessed at www.baxter.com and will be available for replay through August 11, 2022.
  • Every day, millions of patients and caregivers rely on Baxters leading portfolio of critical care, nutrition, renal, hospital and surgical products.
  • For more than 85 years, weve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen.

HospeTrack 2021 Hospital Intelligence Report for Qatar - Covering Over 90 Hospitals and Diagnostic Imaging Centers - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Hospitals, Health, Medical Supplies, Medical devices, Continents, Western Asia, Countries, Arabian Peninsula, Qatar, Health care

As of 2020, Qatar has about 95 healthcare facilities including hospitals, medical centers, and diagnostic imaging centers functioning across all levels of care.

Key Points: 
  • As of 2020, Qatar has about 95 healthcare facilities including hospitals, medical centers, and diagnostic imaging centers functioning across all levels of care.
  • According to HospeTrack Hospital Intelligence for Qatar, the largest opportunity in the immediate term is likely to be around building new healthcare facilities as well as expanding existing facilities.
  • HospeTrack Hospital Intelligence for Qatar, Installed Base Pivot Analysis
    5.
  • HospeTrack Hospital Intelligence for Qatar, IB Base File
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005835/en/

Tandem Diabetes Care Announces Upcoming Conference Presentation

Retrieved on: 
Thursday, July 29, 2021
Diabetes, Health, Medical devices, Health, Tandem Diabetes Care, Organ systems, Diabetes, Medicine

The link to the live webcast and archive will be accessible on Tandem Diabetes Cares Investor Center website located at http://investor.tandemdiabetes.com in the Events & Presentations section.

Key Points: 
  • The link to the live webcast and archive will be accessible on Tandem Diabetes Cares Investor Center website located at http://investor.tandemdiabetes.com in the Events & Presentations section.
  • Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com ) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.
  • Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
  • Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.

Medical Device Contract Manufacturing Market by Device Type, Class of Device, Services and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Medical device, Medical technology, Medical devices, Food and Drug Administration, Wi, Inc., Single-use medical devices

Based on the class of device, the medical device contract manufacturing market is segmented into Class I, Class II, and Class III medical devices.

Key Points: 
  • Based on the class of device, the medical device contract manufacturing market is segmented into Class I, Class II, and Class III medical devices.
  • In 2020, the Class II medical devices segment is projected to grow at the highest CAGR in the medical device contract manufacturing market.
  • Based on service, the medical device contract manufacturing market is segmented into device development and manufacturing services, quality management services, packaging and assembly services, and other services.
  • The increasing adoption of contract manufacturing services in the medical device industry, growth in the medical devices market (especially in the single-use disposable medical devices market), and improving device development and manufacturing capabilities are the major factors responsible for the large share of this segment.